OrbiMed Advisors RNA Position
Active15-Fund ConvergenceOrbiMed Advisors trimmed their position in Avidity Biosciences Inc. (RNA) in Q4 2025, holding $44.7M worth of shares across 619,530 shares.
The position was first reported in Q1 2024 and has been tracked across 8 quarterly 13F filings.
RNA is a convergence signal: 15 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 3 readout for AOC 1001 (del-desiran) in 137 days (Aug 31, 2026), making the timing of OrbiMed's position particularly relevant.
About Avidity Biosciences Inc.
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. The company was incorporated in 2025 and is headquartered in San Diego, California.
Full company profile →OrbiMed Advisors RNA Position History
| Quarter | Action | Shares | Change | Value |
|---|---|---|---|---|
| Q4 2025 | Decreased | 619,530 | -1,019,356 | $44.7M |
| Q3 2025 | Decreased | 1,638,886 | -174,000 | $71.4M |
| Q2 2025 | Held | 1,812,886 | — | $51.5M |
| Q1 2025 | Increased | 1,812,886 | +700,000 | $53.5M |
| Q4 2024 | Increased | 1,112,886 | +68,081 | $32.4M |
| Q3 2024 | Increased | 1,044,805 | +338,330 | $48.0M |
| Q2 2024 | Decreased | 706,475 | -287,625 | $28.9M |
| Q1 2024 | New | 994,100 | +994,100 | $25.4M |
Frequently Asked Questions
Does OrbiMed Advisors own RNA?
Yes. As of Q4 2025, OrbiMed Advisors holds 619,530 shares of Avidity Biosciences Inc. (RNA) valued at $44.7M. This data comes from their SEC 13F filing.
How many hedge funds own RNA?
15 specialist biotech hedge funds currently hold RNA, including RA Capital Management, RTW Investments, Avoro Capital Advisors and 11 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did OrbiMed Advisors first buy RNA?
OrbiMed Advisors's position in RNA was first reported in Q1 2024. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is OrbiMed Advisors's RNA position increasing or decreasing?
OrbiMed Advisors trimmed their RNA position in the most recent quarter, reducing by 1,019,356 shares.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
RNACompany Page →
All fund holders, insider trades, catalysts, and cash runway
OrbiMed AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →